183305-24-0 Usage
Uses
Used in Pharmaceutical Industry:
N-[2-[5-(Aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methylglycine is used as a direct inhibitor of factor Xa (FXa) for its anticoagulant properties. It has been shown to reduce ex-vivo arterial thrombus formation and factor-X activity in a dose-dependent manner, making it a promising candidate for the development of novel anticoagulant therapies.
Additionally, N-[2-[5-(Aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methylglycine may have potential applications in other industries, such as chemical research or material science, depending on its specific properties and characteristics. However, based on the provided materials, the primary use of N-[2-[5-(Aminoiminomethyl)-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methylglycine is within the pharmaceutical industry for its anticoagulant effects.
Check Digit Verification of cas no
The CAS Registry Mumber 183305-24-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,3,0 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 183305-24:
(8*1)+(7*8)+(6*3)+(5*3)+(4*0)+(3*5)+(2*2)+(1*4)=120
120 % 10 = 0
So 183305-24-0 is a valid CAS Registry Number.
InChI:InChI=1/C25H24F2N6O5/c1-33-8-7-31-23(33)14-3-2-4-15(9-14)37-24-20(26)16(11-30-12-19(35)36)21(27)25(32-24)38-18-10-13(22(28)29)5-6-17(18)34/h2-6,9-10,30H,7-8,11-12,28-29H2,1H3,(H,35,36)
183305-24-0Relevant academic research and scientific papers
Benzamidine derivatives and their use as anti-coagulants
-
, (2008/06/13)
This invention is directed to benzamidine derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity.
